Research progress on osteosarcoma treatment in the precision medicine era

VernacularTitle:精准医学时代骨肉瘤诊疗的研究进展*
Author: Zhixuan CHEN ^{1
,

2} ; Yafei JIANG ; Yingqi HUA ; Zhengdong CAI
Author Information

1. 海交通大学附属第一人民医院骨科(上海市200080)
2. 上海交通大学医学院
Keywords: precision medicine; osteosarcoma; genomics; patient derived xenograft (PDX); tumor immunity
From: Chinese Journal of Clinical Oncology 2019;46(17):914-918
CountryChina
Language:Chinese
Abstract: With the rapid development of omics and big data technology, there have been multiple achievements with the use of pre-cision medicine for cancer treatment. Osteosarcoma, the most common primary malignant tumor of the skeletal system, primarily oc-curs in children and adolescents. Since the 1970s, surgical resection and chemotherapy have been the main treatments for osteosarco-ma; however, the survival rate for this type of cancer has been stagnant due to high genetic heterogeneity. Precision medicine can pro-vide a precise diagnosis and tailored treatments based on the patients’biological characteristics using techniques such as omics. Therefore, application of precision medicine is promising for studying osteosarcoma and improving patient survival rates. This study aims to systematically review the progress of precision medicine in advancing osteosarcoma treatment. In addition, it discusses the prospects and future direction of osteosarcoma precision treatment.